Results 251 to 260 of about 126,447 (301)
Some of the next articles are maybe not open access.

Related searches:

Infantile Hemangiomas

Dermatologic Clinics, 2022
Infantile hemangiomas (IHs) are the most common benign vascular tumors of childhood. They develop during the first few weeks of life and naturally progress by proliferating over several months before they involute and resolve; this renders them inconsequential in many cases, but sometimes IHs can have detrimental consequences on function and ...
Divina Justina, Hasbani, Lamiaa, Hamie
openaire   +2 more sources

Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate

Pediatric dermatology, 2022
Early referral and treatment of infantile hemangioma (IH) is a major challenge for treatment success. However, there is a lack of data supporting a specific threshold for initiating treatment with oral propranolol.
C. Léauté-Labrèze   +2 more
semanticscholar   +1 more source

Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age

Pediatric dermatology, 2022
Propranolol is used to treat problematic infantile hemangiomas (IHs), but its safety in infants
Jorie E Gatts   +4 more
semanticscholar   +1 more source

Infantile Hepatic Hemangiomas

New England Journal of Medicine, 2021
Infantile Hepatic Hemangiomas A 16-day-old girl who had not returned to her birth weight was brought to the emergency department with lethargy.
Coen T. Butters, Margot Nash
openaire   +2 more sources

Infantile Hemangioma

Pediatric Clinics of North America, 2010
Infantile hemangiomas (IHs) are the most common soft tissue tumors of childhood. The wide spectrum of disease has made it difficult to predict need for treatment and has made it challenging to establish a standardized approach to management. This article provides the reader with an up-to-date discussion of IH, identifying features of this condition ...
Kristen E, Holland, Beth A, Drolet
openaire   +2 more sources

Infantile and congenital hemangiomas

Seminars in Pediatric Surgery, 2020
Infantile hemangiomas (IHs) are the most common benign tumors of infancy. They typically appear after birth and undergo a period of rapid growth, followed by a gradual period of involution. Although the majority of IHs do not requirement treatment, oral propranolol is the first-line therapy for lesions that are at risk for life-threatening ...
Allison Nackers   +2 more
openaire   +3 more sources

Propranolol Therapy in Infantile Hemangioma: It Is Not Just About the Beta

Plastic and Reconstructive Surgery, 2021
Background: Propranolol, a nonselective β-adrenergic receptor antagonist, is approved by the U.S. Food and Drug Administration to treat problematic infantile hemangiomas, but a subset of patients experience treatment complications.
James C. Lee   +4 more
semanticscholar   +1 more source

Hemangioma Endothelial Cells and Hemangioma Stem Cells in Infantile Hemangioma

Annals of Plastic Surgery, 2021
Background Hemangioma is one of the most common benign tumors in infants and young children. The 2 most important cells in the course of infantile hemangioma (IH) are hemangioma stem cells (HemSCs) and hemangioma endothelial cells (HemECs).
Yuming Sun   +4 more
semanticscholar   +1 more source

Infantile Hemangioma: An Updated Review.

Current pediatric reviews, 2020
BACKGROUND Infantile hemangiomas are the most common vascular tumors of infancy affecting up to 12% of infants by the first year of life. OBJECTIVE To familiarize physicians with the natural history, clinical manifestations, diagnosis, and management ...
A. Leung, J. Lam, K. Leong, K. Hon
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy